{"ATC Code":"N06AX16","Abbreviation":"","Aliases":["D,L-Venlafaxine","Venlafaxina","Elafax","Venlafaxinum","Efectin","velafax","1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol","Venlafexine","Kanghong","Trevilor"],"Biological Half-Life":"The apparent elimination half-life is 5 ± 2 hours for venlafaxine and 11 ± 2 hours for ODV.","CAS":"93413-69-5","ChEBI":"CHEBI:9943","ChEMBL":"CHEMBL637","ChemicalClasses":["phenethylamine"],"Chirality":"racemic","Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Lower":56.25,"Upper":75},"Heavy":{"Lower":131.25,"Upper":150},"Light":{"Lower":37.5,"Upper":56.25},"Strong":{"Lower":75,"Upper":131.25},"Threshold":{"Lower":20,"Upper":37.5}},"Unit":"mg"}],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Serotonin-Norepinephrine Reuptake Inhibitors","Drug Indication":"Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.","Drug Warnings":"/BOXED WARNING/ WARNING: SUICIDAL THOUGHTS AND BEHAVIORS. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older.  In patients of all ages who are started on antidepressant therapy monitor closely for clinical worsening and emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.","DrugClasses":["antidepressant","depressant"],"European Community (EC) Number":"618-944-2","FDA Pharmacological Classification":"GRZ5RCB1QG","FullSalts":["Venlafaxine hydrochloride"],"HMDB ID":"HMDB0005016","HeavyAtomCount":20,"Human Drugs":"Antidepressants -\u003e Serotonin-noradrenaline reuptake inhibitors (SNRI)","IUPACName":"1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol","Impurities":["n-nitroso-desmethyl-venlafaxine"],"InChI":"InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3","InChIKey":"PNVNVHUZROJLTJ-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS. (See all compounds classified as Serotonin and Noradrenaline Reuptake Inhibitors.)","Melting Point":"Crystals from ethyl acetate; melting point 102-104 °C; specific optical rotation: +27.6 deg (c = 1.07 in 95% ethanol) /Venlafaxine (+)form/","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e27\u003c/sub\u003eNO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"277.4 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"Venlafaxine is an antidepressant agent that works to ameliorate the symptoms of various psychiatric disorders by increasing the level of neurotransmitters in the synapse. Venlafaxine does not mediate muscarinic, histaminergic, or adrenergic effects.","Physical Description":"Solid","PrevSalts":["hydrochloride"],"PubChemId":5656,"Record Description":["Venlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group. It has a role as an antidepressant, a serotonin uptake inhibitor, an adrenergic uptake inhibitor, a dopamine uptake inhibitor, an analgesic, an environmental contaminant and a xenobiotic. It is a member of cyclohexanols, a tertiary alcohol, a tertiary amino compound and a monomethoxybenzene.","Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997.  Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD). Venlafaxine was also investigated in off-label uses for the prophylaxis of migraine headaches, for reduction of vasomotor symptoms associated with menopause, and for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).","Venlafaxine is a Serotonin and Norepinephrine Reuptake Inhibitor. The mechanism of action of venlafaxine is as a Norepinephrine Uptake Inhibitor, and Serotonin Uptake Inhibitor.","Venlafaxine is a serotonin and norepinephrine reuptake inhibitor widely used as an antidepressant. Venlafaxine therapy can be associated with transient asymptomatic elevations in serum aminotransferase levels and has been linked to rare instances of clinically apparent acute liver injury.","Venlafaxine is a synthetic phenethylamine bicyclic derivative with antidepressant activity. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak dopamine reuptake inhibitors.  This agent may reduce hormone-related vasomotor symptoms. (NCI04)","VENLAFAXINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA.","Venlafaxine (brand name: Effexor or Efexor) is an effective antidepressant for many persons; Venlafaxine is a bicyclic antidepressant, and is usually categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI), but it has been referred to as a serotonin-norepinephrine-dopamine reuptake inhibitor. It works by blocking the transporter reuptake proteins for key neurotransmitters affecting mood, thereby leaving more active neurotransmitter in the synapse. The neurotransmitters affected are serotonin (5-hydroxytryptamine) and norepinephrine (noradrenaline) Additionally, in high doses it weakly inhibits the reuptake of dopamine; A comparison of adverse event rates in a fixed dose study comparing venlafaxine 75, 225, and 375 mg/day with placebo revealed a dose dependency for some of the more common adverse events associated with venlafaxine use. The rule for including events was to enumerate those that occurred at an incidence of 5% or more for at least one of the venlafaxine groups and for which the incidence was at least twice the placebo incidence for at least one venlafaxine group. Tests for potential dose relationships for these events (Cochran-Armitage Test, with a criterion of exact 2-sided p-value \u003c= 0.05) suggested a dose-dependency for several adverse events in this list, including chills, hypertension, anorexia, nausea, agitation, dizziness, somnolence, tremor, yawning, sweating, and abnormal ejaculation.[Wyeth Monograph]; Venlafaxine is an effective anti-depressant for many persons; however, it seems to be especially effective for those with treatment resistant depression. Some of these persons have taken two or more antidepressants prior to venlafaxine with no relief. Patients suffering with severe long-term depression typically respond better to venlafaxine than other drugs. However, venlafaxine has been reported to be more difficult to discontinue than other antidepressants. In addition, a September 2004 Consumer Reports study ranked venlafaxine as the most effective among six commonly prescribed antidepressants. However, this should not be considered a definitive finding, since responses to psychiatric medications can vary significantly from individual to individual; however, it seems to be especially effective for those with treatment-resistant depression. Some of these persons have taken two or more antidepressants prior to venlafaxine with no relief. Patients suffering with severe long term depression typically respond better to venlafaxine than other drugs. However, venlafaxine has been reported to be more difficult to discontinue than other antidepressants. In addition, a September 2004 Consumer Reports study ranked venlafaxine as the most effective among six commonly prescribed antidepressants. However, this should not be considered a definitive finding, since responses to psychiatric medications can vary significantly from individual to individual; Venlafaxine hydrochloride is a prescription antidepressant that belongs to the class of antidepressants called serotonin-norepinephrine reuptake inhibitors (SNRI). A Black Box Warning has been issued with Venlafaxine and with other SSRI and SNRI anti-depressants advising of risk of suicide. There is an additional risk if a physician misinterprets patient expression of adverse effects such as panic or akithesia. Careful assessment of patient history and comorbid risk factors such as drug abuse are essential in evaluating the safety of Venlafaxine for individual patients. Another risk is Serotonin syndrome. This is a serious effect that can be caused by interactions with other drugs and is potentially fatal. This risk necessitates clear information to patients and proper medical history. Venlafaxine is used primarily for the treatment of depression, generalized anxiety disorder, obsessive compulsive disorder, social anxiety disorder, and panic disorder in adults. It is also used for other general depressive disorders. Although it is not approved for use in children or adolescents, there is a considerable information by Wyeth on cautions if presecribed to this age group. Venlafaxine hydrochloride is a prescription antidepressant first introduced by Wyeth in 1993. It belongs to class of antidepressants called serotonin-norepinephrine reuptake inhibitors (SNRI). As of August 2006, generic venlafaxine is available in the United States.","A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.","See also: Venlafaxine Hydrochloride (has salt form); Venlafaxine Besylate (is active moiety of); Venlafaxine besylate monohydrate (active moiety of).","Venlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group. It has a role as an antidepressant, a serotonin uptake inhibitor, an adrenergic uptake inhibitor, a dopamine uptake inhibitor, an analgesic, an environmental contaminant and a xenobiotic. It is a member of cyclohexanols, a tertiary alcohol, a tertiary amino compound and a monomethoxybenzene.","LiverTox|CNS|Antidepressant|SSRI"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Venlafaxine","Name":"Venlafaxine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q898407","Name":"Venlafaxine","Sub":false},{"Link":"https://www.wikidata.org/wiki/Q82244561","Name":"(+)-Venlafaxine","Sub":true},{"Link":"https://www.wikidata.org/wiki/Q81988295","Name":"(-)-Venlafaxine","Sub":true}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00285","Name":"Venlafaxine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5656","Name":"Venlafaxine","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/9795623","Name":"(+)-Venlafaxine","Sub":true},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/11846746","Name":"(-)-Venlafaxine","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL637","Name":"Venlafaxine","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL251694","Name":"(+)-Venlafaxine","Sub":true},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL252720","Name":"(-)-Venlafaxine","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9943","Name":"Venlafaxine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=93413-69-5","Name":"Venlafaxine","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=93413-46-8","Name":"(+)-Venlafaxine","Sub":true},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=93413-44-6","Name":"(-)-Venlafaxine","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005016","Name":"Venlafaxine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07187","Name":"Venlafaxine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/GRZ5RCB1QG","Name":"Venlafaxine","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/B33212715Z","Name":"(+)-Venlafaxine","Sub":true},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/5FIM3PQD9S","Name":"(-)-Venlafaxine","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6023737","Name":"Venlafaxine","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID90430837","Name":"(+)-Venlafaxine","Sub":true},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID50904847","Name":"(-)-Venlafaxine","Sub":true}]}],"Reported Fatal Dose":"Venlafaxine's toxicity appears to be higher than other SSRIs, with a fatal toxic dose closer to that of the tricyclic antidepressants than the SSRIs. Doses of 900 mg or more are likely to cause moderate toxicity. Deaths have been reported following large ","SMILES":"CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O","Salts":["hydrochloride"],"SaltsAcidCount":[1],"SaltsAmineCount":[1],"SaltsUNII":["7D7RX5A8MO"],"Solubility":"Molecular weight: 313.86. White to off-white crystalline solid from methanol/ethyl acetate, mp 215-217 °C. SOlubility (mg/mL): 572 water. Partition coefficient (octanol/water): 0.43 /Venlafaxine hydrochloride/","StereoisomerRacemic":"(RS)-Venlafaxine","Stereoisomers":["(+)-Venlafaxine","(-)-Venlafaxine"],"StereoisomersUNII":["B33212715Z","5FIM3PQD9S"],"StoreUNII":["GRZ5RCB1QG"],"StructureBase64":"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","Therapeutic Uses":"Antidepressive Agents, Second-Generation; Serotonin Uptake Inhibitors","Title":"Venlafaxine","UNII":"GRZ5RCB1QG","Wikidata":"Q898407","XLogP":2.9,"chemspiderId":5454}